Randomized, phase 3 trial of inotuzumab ozogamicin plus rituximab versus chemotherapy plus rituximab for relapsed/refractory aggressive B-cell non-Hodgkin lymphoma

Br J Haematol. 2018 Aug;182(4):583-586. doi: 10.1111/bjh.14820. Epub 2017 Jul 5.

¹ University of Florida, Gainesville, FL, USA.
² Nagoya Daini Red Cross Hospital, Nagoya, Japan.
³ Tokai Central Hospital, Kakamigahara, Japan.
⁴ University of Versailles Saint-Quentin, Le Chesnay, France.
⁵ University of Texas MD Anderson Cancer Center, Houston, TX, USA.
⁶ Lund University, Lund, Sweden.
⁷ University of Manchester and the Christie NHS Foundation Trust, Manchester Academic Health Science Centre, Manchester, UK.
⁸ Charité-Universitätsmedizin, Berlin, Germany.
⁹ State Medical Academy, Dnepropetrovsk, Ukraine.
¹⁰ University of Calgary, Calgary, AB, Canada.
¹¹ Pfizer Inc, Cambridge, MA, USA.
¹² National Cancer Centre Hospital, Tokyo, Japan.
¹³ Karmanos Cancer Center, Detroit, MI, USA.
¹⁴ Memorial Sloan Kettering Cancer Center, New York, NY, USA.
¹⁵ Hospital Clínic, Barcelona, Spain.
¹⁶ School Medicine, Tokai University, Isehara, Kanagawa, Japan.

No abstract available

Keywords: B-cell non-Hodgkin lymphoma; CD22+; antibody-drug conjugate; inotuzumab ozogamicin; rituximab.

Publication types